Compass Therapeutics, Inc. (CMPX)
NASDAQ:CMPX
Want to see CMPX full AI Analyst Report?
Top Page
Compass Therapeutics
(NASDAQ:CMPX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▼(-58.33% Downside)
Action:Reiterated
Date:05/29/26
The score is primarily constrained by weak financial performance (pre-revenue, sizable losses, and ongoing free-cash-flow burn). Technicals also remain pressured by a broader downtrend and negative MACD despite a short-term bounce. Valuation is difficult to support with a negative P/E and no dividend yield.
Positive Factors
Positive Phase 2/3 clinical results
Robust randomized Phase 2/3 results in second-line biliary tract cancer materially de-risk a lead program. Statistically significant PFS and improved ORR in a disease lacking approved second-line options strengthen regulatory and commercial prospects, boost partnering appeal, and support a durable pathway to potential product revenue and lifecycle planning.
Negative Factors
Pre-revenue, large persistent losses
As a pre-revenue clinical-stage biotech, Compass lacks product-derived cash flow and records large recurring net losses. This structural profitability gap means the company must rely on financing or partnerships to fund operations; absent durable revenue, operational sustainability depends on advancing candidates to approval or securing material non-dilutive deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2/3 clinical results
Robust randomized Phase 2/3 results in second-line biliary tract cancer materially de-risk a lead program. Statistically significant PFS and improved ORR in a disease lacking approved second-line options strengthen regulatory and commercial prospects, boost partnering appeal, and support a durable pathway to potential product revenue and lifecycle planning.
Read all positive factors
Compass Therapeutics (CMPX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$428.61M
Dividend YieldN/A
Average Volume (3M)12.77M
Price to Earnings (P/E)―
Beta (1Y)2.07
Revenue Growth-100.00%
EPS Growth-2.72%
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.42
Shares Outstanding180,087,920
10 Day Avg. Volume5,086,996
30 Day Avg. Volume12,774,032
Financial Highlights & Ratios
PEG Ratio-0.76
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-384.48
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$9.22Price Target Upside53.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.42
Revenue Forecast (FY)-$1.16M
Compass Therapeutics Business Overview & Revenue Model
Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development inclu...
How the Company Makes Money
Compass Therapeutics is a clinical-stage biotech and, as such, it generally does not generate recurring revenue from product sales unless and until a drug candidate receives regulatory approval; the primary funding source is typically external fin...
Compass Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -738.00K | -1.47M | 850.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -72.49M | -71.37M | -54.87M | -48.47M | -39.75M | -80.19M |
| Net Income | -68.17M | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
Balance Sheet | ||||||
| Total Assets | 205.17M | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M |
| Cash, Cash Equivalents and Short-Term Investments | 194.69M | 208.91M | 126.72M | 152.46M | 186.61M | 144.51M |
| Total Debt | 9.79M | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M |
| Total Liabilities | 18.70M | 22.80M | 15.17M | 8.34M | 18.01M | 13.68M |
| Stockholders Equity | 186.47M | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M |
Cash Flow | ||||||
| Free Cash Flow | -53.29M | -49.17M | -44.90M | -40.65M | -34.34M | -21.23M |
| Operating Cash Flow | -53.20M | -49.14M | -44.85M | -40.62M | -34.13M | -19.67M |
| Investing Cash Flow | -66.47M | -93.31M | 46.77M | 26.96M | -151.20M | -1.77M |
| Financing Cash Flow | 133.79M | 129.61M | 17.34M | 2.94M | 75.76M | 118.61M |
Compass Therapeutics Technical Analysis
Negative
6.00
Price Trends
3.68
Negative
4.79
Negative
4.50
Negative
Market Momentum
-0.36
Negative
40.21
Neutral
82.81
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPX, the sentiment is Negative. The current price of 6 is above the 20-day moving average (MA) of 2.00, above the 50-day MA of 3.68, and above the 200-day MA of 4.50, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 40.21 is Neutral, neither overbought nor oversold. The STOCH value of 82.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMPX.
Compass Therapeutics Risk Analysis
Compass Therapeutics disclosed 76 risk factors in its most recent earnings report. Compass Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Compass Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.43B | -9.83 | -1057.44% | ― | ― | -13.14% | |
53 Neutral | $783.73M | -10.34 | -36.61% | ― | -75.91% | -173.33% | |
53 Neutral | $435.71M | -36.68 | -12.84% | ― | ― | 40.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $326.93M | -1.44 | -35.74% | ― | 146.03% | -0.87% | |
45 Neutral | $428.61M | -6.07 | -39.75% | ― | -100.00% | -2.72% | |
43 Neutral | $54.19M | -0.26 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
CMPX
Compass Therapeutics
2.22
0.08
3.74%
KALV
KalVista Pharmaceuticals
26.94
13.59
101.80%
CTMX
CytomX Therapeutics
3.45
0.80
30.19%
GOSS
Gossamer Bio
0.20
-1.02
-83.61%
BCYC
Bicycle Therapeutics
4.53
-3.77
-45.42%
MNPR
Monopar Therapeutics Inc
61.26
29.15
90.78%
Compass Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Positive
Apr 27, 2026
On April 27, 2026, Compass Therapeutics reported full secondary endpoint data from its COMPANION-002 randomized Phase 2/3 trial of tovecimig plus paclitaxel versus paclitaxel alone in 168 patients with second-line biliary tract cancer. The combina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.